Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.

Phase 2A Multi-Centre, Double Blind, Placebo Controlled 3-Way Cross-Over Study To Investigate The Effect Of Single Doses Of PF-00446687 On Sexual Arousal And Sexual Desire In Women Suffering From Female Sexual Dysfunction (FSD).

The purpose of this study is to investigate the effect of up to 200 mg of PF-00446687 on acute sexual arousal and sexual interest in post menopausal females, as well as examining the safety and toleration of the drug.

Inclusion Criteria:

• Women who have evidence of Female Sexual Arousal Disorder.
• Women who experience personal distress due to Female Sexual Dysfunction.
• Post menopausal women aged between 45 and 65 years.

Exclusion Criteria:

• Women whose sexual dysfunction is limited to certain types of stimulation, situation or specific partners.
• Women who experience pain with sexual intercourse or who have a sexual aversion disorder.
• Women suffering from female sexual dysfunction where the cause is treatable, for example inadequately controlled diabetes or thyroid dysfunction.